Clinical trials
Kidney Failure, Chronic trials in Finland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
11 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
| Recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fresenius Medical Care Deutschland GmbH | 2 |
| Astellas Pharma Global Development, Inc. | 1 |
| Hansa Biopharma AB | 1 |
| Heidelberg University | 1 |
| Helsinki University Central Hospital | 1 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 1 |
| Joint Authority for Päijät-Häme Social and Health Care | 1 |
| Rigshospitalet, Denmark | 1 |
| Turku University Hospital | 1 |
| UCB BIOSCIENCES GmbH | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Kidney Failure, Chronic | 11 |
| Acidosis, Lactic | 1 |
| Acquired Immunodeficiency Syndrome | 1 |
| Anemia | 1 |
| Anemia, Aplastic | 1 |
| Cardiovascular Diseases | 1 |
| Coinfection | 1 |
| Delayed Graft Function | 1 |
| Diabetes Mellitus | 1 |
| End Stage Liver Disease | 1 |
Trials
Showing 1 to 11 of 11. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.